In 4Q17, Biogen’s (BIIB) interferons generated revenues of $645 million, which reflected a 6% decline YoY and a 3% decline on a quarter-over-quarter basis.
Thermo Fisher Scientific (TMO) will announce its 4Q17 and fiscal 2017 results on January 31, 2018. It has launched some innovative products and entered into strategic collaborations and partnerships.
AbbVie (ABBV) aims to position its investigational therapy Rova-T (rovalpituzumab tesirine) as a standard of care treatment for patients with SCLC (small cell lung cancer).
Baxter International’s 2017 cash flow Between 9M16 (the first nine months of 2016) and 9M17, Baxter International’s (BAX) cash flow rose by $514 million to $933 million, exceeding its cash flow of $905 million in fiscal 2016. In fiscal 9M17, Baxter had operating cash flow of ~$1.3 billion, up $405 million from fiscal 9M16. In fiscal 2017, Baxter expects to […]
On December 28, Becton, Dickinson and Company (BDX), or BD, received clearance for its Bard (BCR) acquisition form MOFCOM (Ministry of Commerce of the People’s Republic of China), but the approval is contingent on the divestment of BD’s soft tissue core needle biopsy product line.
On December 4, 2017, Leerink Swan reiterated its “overweight” rating on TMO stock. The investment research firm has a 12-month target price of $200.00 per share on the stock.
On December 12, 2017, Argus Research analyst John Eade upgraded Medtronic (MDT) stock from a “hold” to a “buy.” He has a price target of $95.00 per share on the stock.
In 3Q17, Bristol-Myers Squibb’s (BMY) Baraclude generated revenues of $264 million, a ~14% decline on a year-over-year (or YoY) basis and a 3% decline on a quarter-over-quarter basis.
BSX’s EPS estimate for 3Q17 represents YoY (year-over-year) growth in the range of 9%–16%. In 2Q17, Boston Scientific registered EPS growth of 18.5% YoY.
Medtronic (MDT) expects its diabetes business to witness a temporary sequential drop in revenues in 2Q18 and then return back to growth in the second half of fiscal 2018.
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
Becton Dickinson (BDX) is the leading player in the US dispensing business. Its Pyxis system sales contribute significantly to the company’s total revenues.
Proton therapy market opportunities The proton therapy market is a highly lucrative opportunity area for Varian Medical Systems (VAR). Proton therapy uses protons for treating cancer instead of X-rays. According to a Medgadget report, the global proton therapy market is expected to double by the year 2022. Though the United States has the biggest proton […]
For fiscal 1Q18, Kors’s EPS came in at $0.90, or $0.28 higher than the estimate. Its revenue fell 3.6% YoY to $952 million but still beat the consensus estimate.
To further expand the label of its transcatheter heart valve (or THV), SAPIEN 3, Edwards Lifesciences (EW) is currently involved in enrolling patients in its EARLY-TAVR trial.
In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.
After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.
Although the ETF industry posted stellar growth, no one thought of issuing an ETF dedicated to ETF providers. The gap was filled by TETF in April 2017.
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
On April 4, 2017, AbbVie announced that the FDA had accepted for review the company’s application seeking approval for Imbruvica as a treatment option for patients suffering from cGVHD.
Gilead Sciences (GILD) is also investigating investigational therapy, entospletinib, as a treatment option for acute myeloid leukemia (or AML) as well as Diffuse Large B-cell Lymphoma (or DLBCL).
In 3Q16, Bristol-Myers Squibb (BMY) secured reimbursement for Opdivo in Sweden and Denmark. After its commercial launch, Opdivo also witnessed solid uptake in France and Germany.
On November 29, 2016, Nevro Corp. (NVRO) filed a lawsuit against Boston Scientific, claiming patent infringement on its patents for Senza and HF10 spinal cord stimulation therapies for chronic back pain.
Thermo Fisher Scientific’s business consists of four complementary businesses: Analytical Instruments, Specialty Diagnostics, Life Science Solutions, and Laboratory Products and Services.
AbbVie’s (ABBV) Venclexta has been granted FDA breakthrough therapy designation as a first line therapy for patients with acute myeloid leukemia who are ineligible for high-dose chemotherapy.
To diversify its product portfolio, AbbVie (ABBV) has been focusing on patients with neurodegenerative disorders such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease.
On October 19, 2016, AbbVie (ABBV) and Neurocrine Biosciences (NBIX) announced positive results from two phase 3 clinical trials at the 72nd American Society for Reproductive Medicine Scientific Congress & Expo.
A bull run with legs In Richard Bernstein Advisors’ October Insights newsletter, after dismissing the belief that the Federal Reserve is to blame for stock price inflation (IWD) (VTV), Richard Bernstein moved on to explain the reason for the current bull run. Stating that “fundamentals have improved dramatically, and have been a major support to the […]
Nonalcoholic steatohepatitis (or NASH) doesn’t have any existing approved treatments on the market, but a number of companies are vying for a share of the untapped market.
The benefits of robotic-assisted ventral hernia repair surgery were substantiated by study results released by Intuitive Surgical (ISRG) in early August 2016.
According to Richard Bernstein, the five charts in the recent edition of his newsletter are “five of our favorite charts that highlight what we think consensus is currently missing.”
While many companies are moving toward fee-for-service models and bundled payment structures, BSX is advancing through its category leadership strategy.
From September 2011 to August 2016, US crude production has risen by 46% to ~8.5 million barrels per day. Production reached a multiyear high in June 2015.
Following Jazz Pharmaceuticals’ announcement of its acquisition of Celator, Jazz stock fell marginally. A higher premium for Celator might be one of the reasons for the fall.
With only one approved drug as a second-line therapy for SCLC (and no approved third-line treatment) AbbVie expects Rova-T to reach a high unmet demand.
In fiscal 2016, Foot Locker made $5.3 billion in US sales, representing 71.6% of its total revenue. In contrast, international revenue came in at $2.1 billion.
Edwards Lifesciences (EW) reported ~$697 million in total revenue in 1Q16. Of that, ~$134 million was contributed by the company’s Critical Care segment.
Under Armour’s (UA) footwear business registered an impressive 64.2% growth (VUG) rate in 1Q16 versus 1Q15. Footwear sales came in at $264 million in the quarter.
Jazz Pharmaceuticals’ Defitelio is the first and only approved treatment that increases survival in VOD patients with multi-organ dysfunction (or MOD).
Lululemon (LULU) stock rose 10.7% to $67.80 on March 30, 2016, the day the company declared its fourth quarter results. The stock has risen more than 29% year-to-date.
